The payment is a part of $21m DARPA milestone awards to be earned by Medicago under a technology investment agreement to demonstrate the scalable manufacturing of its plant-expressed VLP vaccines in US.
Medicago has received $19.8m to date for this project, with two milestones remaining.
Medicago US operations vice president Mike Wanner said that continuing to successfully advance the technology-transfer project is a further demonstration of their robust science and manufacturing platform.
"This milestone focused on documentation related to a phased commissioning approach to the cGMP facility and equipment," Wanner added.